In our study, although SGLT2 inhibitors showed no significant benefit on total stroke; the CANVAS program and the CREDENCE trial showed that there were heterogeneity effects on renal function and a significant risk reduction of stroke in, especially for subjects with lower eGFR. The gene discussed is SLC5A2; the disease is stroke disorder.